Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
In draft guidance produced by its Highly Specialised Technologies program, England and Wales medicines watchdog the National Institute for Health and Care Excellence (NICE) has today asked for further clarification from US biotech firm PCT Therapeutics on the size of the benefit its drug Translarna (ataluren) provides in the treatment of a type of Duchenne muscular dystrophy (DMD). 16 October 2015
The UK’s University College London (UCL) and Japan’s largest drugmaker Takeda Pharmaceutical have entered into a new research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease. 14 October 2015
The US Food and Drug Administration has advised Collegium Pharmaceuticals that it will not be able to complete its review of the New Drug Application for Xtampza ER (oxycodone) extended-release capsules by the Prescription Drug User Fee Act (PDUFA) action date of October 12, 2015. 13 October 2015
Genentech, a unit of Roche (SIX: ROG), has announced results from three studies showing that ocrelizumab was superior to Rebif (interferon beta-1a) from Merck KGaA in patients with relapsing multiple sclerosis. 9 October 2015
Almirall presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in multiple sclerosis (MS), at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Barcelona. 9 October 2015
Biogen and AbbVie have reported positive results in a Phase III study of once-monthly investigational Zinbryta (daclizumab high-yield process) in multiple sclerosis. 8 October 2015
US biotech firm Neurocrine Biosciences says that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. 8 October 2015
Teva Pharmaceutical Industries today revealed that the Russian Ministry of Health has approved the Marketing Authorization license for three-times-a-week Copaxone (glatiramer acetate injection) 40mg/mL, a new dose of the drug for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). 8 October 2015
Positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS) will be presented today at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, by Genzyme. 8 October 2015
TauRx Pharmaceuticals on Thursday said it has completed the final tranche of a $135 million equity financing launched in March to aid late-stage trials for its drugs to treat Alzheimer's and frontotemporal dementia. 8 October 2015
Belgian pharma company UCB has announced positive results of a Phase III non-inferiority study on lacosamide compared to carbamazepine-CR as a monotherapy in newly or recently-diagnosed adult patients with partial-onset seizures. 8 October 2015
Bionomics Limited said pharma giant Merck & Co will buy about 21.7 million shares in the company for a total of $9 million and extended the partnership to develop new pain medication. 8 October 2015
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to around $20 billion by 2024, at a compound annual growth rate (CAGR) of 1.5%, new research indicates. 7 October 2015
US drugmaker The Medicines Company joined forces with Japanese specialty drug firm SymBio Pharmaceuticals for the commercialization of Ionsys (fentanyl iontophoretic transdermal system) in Japan. 7 October 2015
French drug major Sanofi along with its unit Genzyme on Wednesday said a late-stage trial for its drug to treat relapsing multiple sclerosis (RMS) showed it significantly slowed brain volume loss. 7 October 2015
Ireland-headquartered biotech firm Alkermes on Tuesday said the US Food and Drug Administration has approved its drug to treat schizophrenia and that it is looking to immediately launch for the product. 6 October 2015
Biopharma company XenoPort has replaced its chief executive at a moment when the company is refocusing its strategic efforts, causing shares to rise 12%. 5 October 2015
Regeneron Pharmaceuticals has entered into a collaboration with Mitsubishi Tanabe Pharma providing the Japanese drug major with exclusive development and commercial rights to fasinumab (REGN475). 2 October 2015
Independent French drugmaker Ethypharm says it has acquired 100% of the share capital of DB Ashbourne Group (DBA), a branded pharmaceutical business established in the UK in 2009. 2 October 2015